Skip to main content
Equibles
RDGL logo

RDGL · Vivos Inc

Track RDGL — free

Use RDGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RDGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.04 0.00 (-0.23%) At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The independent registered public accounting firm has expressed substantial doubt about the Company's ability to continue as a going concern due to limited revenue, nominal cash, and accumulated deficits since inception. Management plans to pursue additional funding through debt and equity financing (including the pending 2026 Regulation A+ Offering), enhance operating performance via strategic focus on core products, process efficiencies, and cost structure improvements. There can be no assurance of success in raising working capital or achieving profitable operations, and the financial statements include no adjustments for outcomes of this uncertainty.”
View the 10-Q filed Aug 12, 2026
Market Cap
$21.75M
Shares
494.21M
Volume · Nov 12 385.04K Avg daily vol (3M) 775.53K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.04 Open$0.04 Day$0.04–0.04 52W close$0.04–0.09 Avg vol 30d796K Short int124K · 0.0% of shares · 1.0d Short vol54% DataJan 2020–Nov 2026 Filing10-Q · Aug 12

Latest documents

2026
Nov 5
Current report 8-K Events of Oct 30
Vivos raises $1,000,000 and issues warrants for 25,000,000 shares

Vivos Inc completed a $1,000,000 Regulation A+ offering on October 30, 2026, issuing 12,500,000 common shares, sold warrants for 25,000,000 shares for $25,000 at $.075 per share, and issued 8,000,000 shares for warrant cancellation.

Unregistered sale of equity, Shareholder director nominations, Other events
4 source passages
On October 30, 2026, Vivos Inc. (the “Company”) completed the sale and issuance of 12,500,000 shares of common stock, par value $0.001 per share (“Common Stock”), pursuant to its Regulation A+ offering being conducted on a “best efforts” basis under Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “Securities Act”) (the “Offering”). The Offering resulted in gross proceeds to the Company of $1,000,000. On October 30, 2026, the Company completed the sale and issuance to certain accredited investors of warrants to purchase 25,000,000 shares of its Common Stock (the “Warrants”), in consideration of an aggregate of $25,000, which warrants expire, if not previously exercised, on December 31, 2030, and are exercisable for Common Stock at $.075 per share. On October 30, 2026, the Company completed the issuance of 8,000,000 shares of Common Stock (the “Exchange Shares”) in consideration for the cancellation of 8,000,000 warrants to purchase shares of Common Stock (the “Warrant Exchange”). Open the document at this passage
Oct 5
Current report 8-K Events of Sep 28
Charter or bylaw amendment, or fiscal year change

Vivos Inc’s Board adopted Series D Convertible Preferred Stock on September 23, 2026; the certificate was filed on September 28, 2026, designating 1.0 million shares with $1.00 stated value, $1.00 liquidation preference and $0.08 conversion price.

Read from the first part of this long document
Aug 12
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $36.4K ▲ 142.7% Net loss $830.19K Diluted EPS $0.00
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$99,099
Trailing 12 months
Net income (TTM)
−$3.60M
Trailing 12 months
Revenue growth YoY
+142.7%
Year over year
Operating margin
-2,852.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.2%
Year over year · more shares
Price change (1Y)
-52.0%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▼28.6% $5,000 −$825,263 '24 Q3 · −$18,005 −$1.02M '24 Q4* ▲494.4% $26,748 −$834,696 '25 Q1 ▲11.1% $15,000 −$645,513 '25 Q2 ▼62.4% $1,879 −$507,294 '25 Q3 · $24,752 −$1.08M '25 Q4* ▲34.8% $36,068 −$1.18M '26 Q1 LATEST ▲142.7% $36,400 −$830,189 '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 18.7 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −31%
below
Price vs 50-day avg −5%
below
RSI (14) 46
neutral
MACD trend Positive
52-week position 4%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −37%
trailing
YTD return −36%
this year
Relative strength −39%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Accumulating
Net +$100.8K over 90 days · 0% sells
Short interest Rising
0.03% of shares out · ▲ +3213.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Squeeze score 37
low risk · 0–100
Fundamentals
Fair
Revenue growth +23%
Y/Y
Gross margin -1196%
contracting
EPS growth 0%
Y/Y
Free cash flow $-2.2M
Balance sheet $52.6K
net cash
Quant / Vol
risk profile
Very High
Volatility 88%
annualized · 1-yr
Max drawdown −54%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−31% Bearish
Price vs 50-day avg
−5% Bearish
RSI (14)
46 Neutral
MACD trend
Positive Bullish
52-week position
4% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Accumulating
Net +$100.8K over 90 days · 0% sells
Short interest Rising
0.03% of shares out · ▲ +3213.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0 Now $0 · 4% Range high $0
vs 200-day avg -31% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RDGL
Vivos Inc
this stock
$21.75M -36.1% +144.3% — 0.0%
ABT
Abbott Laboratories
 $185.75B -14.4% +5.7% 40.0 1.1%
MDT
Medtronic plc
 $129.18B +5.1% +8.4% 24.9 1.8%
SYK
Stryker Corp
 $118.92B -11.1% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
 $64.07B -53.6% +12.5% 18.7 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
1
% held
0.0%
Net QoQ
0 sh
Top holder
CAPTRUST FINANCIAL ADVISO…
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
124.2K
Days to cover
1.0d
Change
+120.4K sh
View
Short Volume
Short vol %
54%
As of
Nov 12, 2026
Short Total
View
Fails to Deliver
FTD shares
76.7K
Value
$3.8K
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
98.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$100.8K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$68.4K
Net income (FY)
$-3.1M
EPS diluted
$-0.01
View
Filings
SEC Filings
Latest
DEF 14A
Filed
Nov 9, 2026
This year
7
View

Performance

5D 20D 120D MTD YTD
RDGL +4.3% -9.3% -37.0% -1.8% -36.1%
SPY +3.3% -1.9% +1.5% +0.2% +11.0%
vs SPY +1.0% -7.4% -38.5% -2.0% -47.2%
Key facts CIK 1449349 CUSIP 92858K204 Visit website Investor relations